Injecting hBMSCs in HFD/STZ-T2D model, during different disease phases: early (at day 7) vs. late (at day 21) of STZ injection, showed positive impact on beta-cell insulin content, during the early phase treatment. This evidence concerns the gene INS and type 2 diabetes mellitus.